An intact classical pathway of the complement system is essential for protection against immune complex diseases. C1q is a central molecule in the first step of the classical complement activation pathway. The globular heads of C1q bind to the Fc regions of immunoglobulins IgM or IgG thus inducing an activation of the other subcomponents of C1, C1r and C1s.
The presence of Anti-C1q autoantibodies is associated with several autoimmune and renal illnesses. Containing an occurrence of 100% in the hypocomplementaemic uricarial vasculitis syndrome (HUVS), Anti-C1q autoantibodies act as a diagnostic marker for this disease [7]. They were also described in systemic lupus erythemathodes (SLE) and especially in lupus nephritis. It was discovered that up to 60% of patients with SLE [2] and up to 80% of patients with diffuse proliferative lupus nephritis have such antibodies. Anti-C1q autoantibodies were also reported in various other rheumatic diseases such as FELTY's syndrome, rheumatoid vasculitis or classic polyartritis nodosa.
Serial measurement of Anti-C1q titers will be an effective tool for the guidance of immunosuppressive therapy in SLE patients. |
|
|
 |
 |
|
| Tests |
12 x 8 tests |
|
|
|
|
| Calculation |
quantitative |
|
|
|
|
| Range |
0- 100 U/ml |
|
|
|
|
| Cut-off |
10 U/ml |
|
|
|
|
| Sensitivity |
1,0 U/ml |
|
|
|
|
| Calibration |
arbitrary |
|
|
|
|
| Substrate |
TMB / 450 nm |
|
|
|
Instruction for Use: ORG 549-0507-01-gb.pdf
Material-Safety-Datasheet: ORG 549-msds-v2.pdf